Although IGFBP5 has not been studied in the context of drug resistance in ovarian cancer, a bioinformatic analysis of cisplatin resistant ovarian cancer cell lines identified IGFBP5 as significantly downregulated when compared to the parental cell line (118). The gene discussed is IGFBP5; the disease is ovarian carcinoma.